Daclatasvir - Isotope Labelled Standards
References
FAQ's
References
- Bachand, Carol; Belema, Makonen; Deon, Daniel H.; Good, Andrew C.; Goodrich, Jason; James, Clint A.; Lavoie, Rico; Lopez, Omar D.; Martel, Alain; Meanwell, Nicholas A.; et al, Hepatitis C virus inhibitors, Bristol-Myers Squibb Company, United States, US8329159B2, December 11, 2012
- Jiang, Hao; Zeng, Jianing; Kandoussi, Hamza; Liu, Yifei; Wang, Xiaodong; Bifano, Marc; Cojocaru, Laura; Ryan, John; Arnold, Mark E., A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine, Journal of Chromatography A, Volume: 1245, Pages: 117-121, 2012
Frequently Asked Questions
How are raw materials tested for impurities in Daclatasvir production?
Rigorous quality control procedures, including testing and qualification of raw materials, are implemented to ensure their purity and suitability for Daclatasvir manufacturing.
Can Daclatasvir impurities impact its therapeutic efficacy?
Some impurities in Daclatasvir may affect its therapeutic efficacy by interfering with its mechanism of action or causing undesired effects in the body.
Which solvent helps in the analysis of Daclatasvir impurities?
Methanol or water are the solvents used in analyzing many impurities in Daclatasvir.
What are the temperature conditions required to store Daclatasvir impurities?
Daclatasvir impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.